IMVT
Immunovant, Inc. [IMVT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMVT Stock Summary
Top 10 Correlated ETFs
IMVT
Top 10 Correlated Stocks
IMVT
In the News
IMVT Financial details
Company Rating
-
Market Cap
4.26B
Income
-243.45M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
164
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-22.5
Forward P/E
-
PEG
-7.85
P/S
-
P/B
22.81
P/C
-
P/FCF
-30.19
Quick Ratio
6.74
Current Ratio
7.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.84
EPS next Y
-
EPS next Q
-
EPS this Y
19.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20%
-
-
-
-
SMA20
13.84%
SMA50
-8.13%
SMA100
-31.77%
Inst Own
-
Inst Trans
-
ROA
-87%
ROE
-77%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
14.11-45.58
52W High
-65.2%
52W Low
+11.86%
RSI
52.17
Rel Volume
0.95
Avg Volume
1.14M
Volume
1.09M
Perf Week
2.09%
Perf Month
-1.51%
Perf Quarter
-40.34%
Perf Half Y
-45.79%
-
-
-
-
Beta
0.697
-
-
Volatility
0.38%, 0.88%
Prev Close
-1.76%
Price
15.66
Change
-1.82%
Company Profile
- Volume Average 1.14M
- Market Capitalization 4.26B
- Employee 164
- CEO Dr. Peter Salzmann M.B.A., M.D.
- Headquarters New York,NY,US
- IPO Date 2019-06-21
-
Website
https://immunovant.com 
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
